References
- Kim HS, Jeong CW, Kwak C, Kim HH, Ku JH. Novel nomograms to predict recurrence and progression in primary non-muscle-invasive bladder cancer: validation of predictive efficacy in comparison with European Organization of Research and Treatment of Cancer scoring system. World J Urol. 2019;37(9):1867–1877. doi:https://doi.org/10.1007/s00345-018-2581-3.
- Xylinas E, Kent M, Kluth L, et al. Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder. Br J Cancer. 2013;109(6):1460–1466. doi:https://doi.org/10.1038/bjc.2013.372.
- Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466–465. discussion 475-7. doi:https://doi.org/10.1016/j.eururo.2005.12.031.
- Fernandez-Gomez J, Madero R, Solsona E, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol. 2009;182(5):2195–2203. doi:https://doi.org/10.1016/j.juro.2009.07.016.
- Pi J, Xiong Y, Liu C, et al. A nomogram model to predict recurrence of non-muscle invasive bladder urothelial carcinoma after resection based on clinical parameters and immunohistochemical markers. J Invest Surg. 2022;35(5):1186–1194. doi:https://doi.org/10.1080/08941939.2021.2017080.
- Balar AV, Kamat AM, Kulkarni GS, et al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol. 2021;22(7):919–930. doi:https://doi.org/10.1016/S1470-2045(21)00147-9.
- Malmström PU, Sylvester RJ, Crawford DE, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol. 2009;56(2):247–256. doi:https://doi.org/10.1016/j.eururo.2009.04.038.
- van Rhijn BW, Zuiverloon TC, Vis AN, et al. Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. Eur Urol. 2010;58(3):433–441. doi:https://doi.org/10.1016/j.eururo.2010.05.043.
- Zamboni S, Moschini M, Simeone C, et al. Prediction tools in non-muscle invasive bladder cancer. Transl Androl Urol. 2019;8(1):39–45. doi:https://doi.org/10.21037/tau.2019.01.15.
- Necchi A, Raggi D, Gallina A, et al. Molecular subtyping and immune-gene signatures identify a subset of early bladder tumors as candidates for single-agent immune-checkpoint inhibition. Urol Oncol. 2021;39(10):734.e11–e17. doi:https://doi.org/10.1016/j.urolonc.2021.06.011.
- Soliman NA, Yussif SM. Ki-67 as a prognostic marker according to breast cancer molecular subtype. Cancer Biol Med. 2016;13(4):496–504. doi:https://doi.org/10.20892/j.issn.2095-3941.2016.0066.